Cell Therapy Manufacturing Is Hitting a Scalability Wall And Most Companies Are Unprepared
The promise of personalized medicine is colliding with industrial reality. As CAR-T therapies and regenerative treatments move from clinical trials to commercial scale, manufacturers are discovering that manual processing methods cannot support the volume, consistency, or economics required for mass adoption.
Request Report Sample: https://marketmindsadvisory.co....m/request-sample/?re
Why Manual Processing Is No Longer Viable
Cell therapy manufacturing today resembles artisan production in an industry demanding automotive